Home
 »  News
 »  Feature_Story
 »  Celebrex: A New Choice for Arthritis Pain Relief
KNEE1 NEWS: Feature Story
Printer Friendly Version     Email this Article     Links/Reuse

Celebrex: A New Choice for Arthritis Pain Relief


February 22, 2000 | 
By Janelle Mallett, Knee1 Staff

After receiving FDA approval in December 1998, Serle Corporation’s Celebrex is becoming the top choice for prescription arthritis pain relief, defeating other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) including naproxen and ibuprofen. On February 22nd, one year after its initial launch, Celebrex has become the most successful pharmaceutical endeavor in American history.

In acquiring 19 million prescriptions in its first year, Celebrex has surpassed even Viagra and Lipitor, two major US successes. The drug has also managed a high percentage of patients continuing with their medication.

A major part of the successful Celebrex sales can be attributed to effective marketing strategies. Rival drug companies, Searle and Pfizer co-promoted Celebrex in an attempt to benefit mutually from increased sales.

Celebrex has been tested in more than 50 clinics with over 13,000 patients between the ages of 18 and 93. Studies show the drug is as effective as the NSAIDs naproxen and diclofenac in treating the diseases osteoarthritis and rheumatoid arthritis, respectively. The advantage is that Celebrex may be considered safer because of its reduced side effects.

Like naproxen and ibuprofen, Celebrex targets the COX-2 enzyme that synthesizes prostaglandin, the chemical controlling arthritis pain, fever, tenderness and inflammation. These drugs inhibit the COX-2 enzyme, decreasing prostaglandin production and reducing pain and swelling.

Osteoarthritis (OA) is caused by overuse of joints and degeneration of cartilage from normal activities and also from injuries. OA is common among the elderly and affects a significant portion of adults over 35 years. Rheumatoid arthritis (RA) not only affects joints but can also lead to loss of appetite and other problems. Like Osteoarthritis, RA causes pain in joint tissue from cartilage wearing away. The symptoms range from mild pain, to serious joint deformities.

While the other NSAIDs also target the COX-1 enzyme that irritates the stomach as a side effect, Celebrex does not. In various studies Celebrex patients show fewer side effects associated with the stomach lining, including ulcers and stomach bleeding.

Celebrex, however, does have other side effects and still affects the stomach lining, even if to a lesser extent. Use of the COX-2 inhibitor can cause indigestion, diarrhea and abdominal pain. In some rare instances, stomach bleeding may occur. Another advantage Celebrex has over other NSAIDs is that it will not restrict blood clotting.

Merck and Co. has also won FDA approval on a COX-2 inhibitor arthritis pain killer, under the brand name Vioxx. The market is growing fast and furiously with companies promoting that COX-2 inhibitors are safer than other NSAID pain-killers.

Patients should be aware, however, that studies on the long-term effects of Celebrex are not yet available.
Bookmark and Share

Previous Stories

Camby's Injury Not As Bad As Feared

Dolphins' Sam Madison Has Surgery

Hormone May Cause Knee Injuries

more Feature Stories


RSS  
Forgot information?
Login problem??

The best way to stretching
By mayolarubilt
more more Blogs RSS

Meet in the FORUMS
Knee giving out? Slightly worried.
By symaraalerman

Posted: May 19, 2012
18 year old, female soccer player. I tore my ACL in april 2011, and underwent ACL reconstruction surgery with a hamstring graft the first week of october 2011. It's been about 7 months since. I've bee

more more Forums
Create a Topic

Reducing Sport Injuries in children
Reducing Sports Injuries in Children
Learn important tips on how to avoid sports injuries, specifically for ...
more more Featured Videos

 
Dr. Cynthia LaBella
Dr. Cynthia LaBella:
Preventing Knee Injuries in Young Athletes
  more   more Heroes
  Nominate a Hero   Hero Policy
Home | About Us | Press | Make a Suggestion | Content Syndication | Terms of Service
Privacy Policy | Advertising Policy | Editorial Policy
Last updated: Sep 19, 2011  ©1999- 2012 Body1 All rights reserved.